var data={"title":"Osteogenesis imperfecta: Clinical features and diagnosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Osteogenesis imperfecta: Clinical features and diagnosis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">John F Beary, III, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Arkadi A Chines, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Helen V Firth, DM, FRCP, DCH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Elizabeth TePas, MD, MS</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Aug 21, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Osteogenesis imperfecta (OI) is an inherited connective tissue disorder with many phenotypic presentations. It is often called &quot;brittle bone disease.&quot; Severely affected patients suffer multiple fractures with minimal or no trauma, and infants with the worst form of OI die in the perinatal period. Mild forms of OI may manifest with only premature osteoporosis or severe postmenopausal bone mineral loss.</p><p>The pathogenesis, clinical features, diagnosis, and differential diagnosis of OI are presented here. The management and prognosis of OI are discussed separately. (See <a href=\"topic.htm?path=osteogenesis-imperfecta-management-and-prognosis\" class=\"medical medical_review\">&quot;Osteogenesis imperfecta: Management and prognosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The estimated incidence of OI is approximately 1 per 20,000 births [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/1\" class=\"abstract_t\">1</a>]. This qualifies it as an orphan disease, which is defined in the United States as a disease affecting 200,000 patients or less.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The cause of OI is established in most cases. In patients with identified molecular defects, OI is most commonly caused by mutations in genes encoding the alpha-1 and alpha-2 chains of type I collagen [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/2\" class=\"abstract_t\">2</a>] or proteins involved in posttranslational modification of type I collagen. Type I collagen fibers are polymers of tropocollagen molecules, each of which is a triple helix that contains portions of one alpha 2 and two alpha 1 polypeptide chains. The composition of tropocollagen is shown in the figure (<a href=\"image.htm?imageKey=ENDO%2F77562\" class=\"graphic graphic_figure graphicRef77562 \">figure 1</a>). Type I collagen is an important structural protein for bone, tendon, ligament, skin, and sclerae. Defective bone quality explains many clinical aspects of OI. (See <a href=\"topic.htm?path=bone-physiology-and-biochemical-markers-of-bone-turnover#H4\" class=\"medical medical_review\">&quot;Bone physiology and biochemical markers of bone turnover&quot;, section on 'Bone formation'</a>.)</p><p>Most patients with OI have an autosomal dominant mutation in <em>COL1A1</em> (located at 17q21.31-q22) or <em>COL1A2</em> (located at 7q22.1) that affects the structure of one of the two alpha chains of type I collagen. The severity of the clinical presentation depends upon the effect of the mutation (<a href=\"image.htm?imageKey=PEDS%2F78737\" class=\"graphic graphic_table graphicRef78737 \">table 1</a> and <a href=\"image.htm?imageKey=PEDS%2F73256\" class=\"graphic graphic_table graphicRef73256 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/3-7\" class=\"abstract_t\">3-7</a>]. As an example, mutations in <em>COL1A1</em> or <em>COL1A2</em> that lead to decreased amounts of normal collagen cause the mild phenotype seen in type I OI. In contrast, mutations that disrupt the formation of the normal type I collagen triple helix cause the lethal phenotype seen in type IIA OI. Other <em>COL1A1</em> and <em>COL1A2</em> mutations that result in structural protein defects cause moderate (type IV) and severe, but not lethal (type III), forms of OI.</p><p><em>COL1A1</em> and <em>COL1A2</em> genes are normal in approximately 10 percent of cases. Many of these patients have autosomal recessive genetic defects.</p><p>A recurrent mutation (c.-14C&gt;T) in the 5&rsquo; untranslated region (UTR) of the interferon-induced transmembrane protein 5 (<em>IFITM5</em>) gene located at 11p15.5 is the cause of OI type V in several families and also in simplex cases [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/8,9\" class=\"abstract_t\">8,9</a>]. Expression of this protein, which is thought to be involved in bone formation and osteoblast maturation, is highly restricted to skeletal tissue.</p><p>Mutations in the FK506-binding protein 10 (<em>FKBP10</em> or <em>FKBP65</em>) gene, located at 17q21, were identified in a cohort of five consanguineous Turkish families and in a Mexican-American family with recessively inherited, moderately severe OI [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/10\" class=\"abstract_t\">10</a>]. <em>FKBP10</em> encodes a molecular chaperone that interacts with type I collagen and tropoelastin and is involved in the folding of type I procollagen. Mutations in <em>FKBP10</em> affect type I procollagen secretion. The OI phenotype associated with <em>FKBP10</em> mutations (designated OI type VI) most closely resembles OI type III because of its severity and progressive nature. However, histologic findings of distorted lamellar structure and elevated alkaline phosphatase in some of the affected children are consistent with OI type VI. Mutations in <em>FKBP10</em> can cause a related disorder, Bruck syndrome. (See <a href=\"#H17\" class=\"local\">'Other skeletal syndromes'</a> below.)</p><p>Mutations in any of the three components of the 3-prolyl-hydroxylation complex that modifies type I collagen posttranslation can cause <span class=\"nowrap\">lethal/severe,</span> recessive forms of OI with normal collagen folding. These components include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cartilage-associated protein (<em>CRTAP</em>, gene located at 3p22) [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/11,12\" class=\"abstract_t\">11,12</a>]. CRTAP deficiency was detected in 3 of 10 children with recessively inherited lethal or severe OI who had type I collagen with normal primary structure, but excess posttranslational modification of the alpha chain helical regions [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/13\" class=\"abstract_t\">13</a>]. Mutations in <em>CRTAP</em> cause type IIB OI (a perinatal lethal form) and type VII OI (a severe, nonlethal form) [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/13-15\" class=\"abstract_t\">13-15</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prolyl-3-hydroxylase-1 (P3H1; encoded by leprecan-like 1 [<em>LEPRE1</em>], located at 1q34) [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/16,17\" class=\"abstract_t\">16,17</a>]. Mutations in <em>LEPRE1</em> cause type VIII OI [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/12,17-19\" class=\"abstract_t\">12,17-19</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Peptidyl-prolyl isomerase B (also called cyclophilin B; <em>PPIB</em> gene located at15q21-q22). Mutations in <em>PPIB</em> cause type IX OI [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/20-22\" class=\"abstract_t\">20-22</a>].</p><p/><p>Mutations causing severe, recessive OI resembling type III OI have also been identified in other genes encoding proteins involved in bone formation and homeostasis. These include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>SERPINH1</em> (located at 11q13.5), which encodes a collagen chaperone-like protein (serpin peptidase inhibitor, clade, H, member 1; also called collagen-binding protein 2 [CBP2]; and heat-shock protein 47 [HSP47]) [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/23\" class=\"abstract_t\">23</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>SERPINF1</em> (located at 17p13.3), which encodes a multifunctional glycoprotein that is a strong inhibitor of angiogenesis (serpin peptidase inhibitor, clade F, member 1; also called pigment epithelium-derived factor [PEDF]) [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/24\" class=\"abstract_t\">24</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em><span class=\"nowrap\">SP7/OSX</em></span> (located at 12q13.13), which encodes specificity protein 7 or osterix, a zinc finger transcription factor that is an essential regulator of bone cell differentiation [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/25\" class=\"abstract_t\">25</a>].</p><p/><p>Homozygous or compound heterozygous mutations in <em>WNT1</em>, the gene encoding wingless-type mouse mammary tumor virus integration site family member 1, have been identified as the cause of a recessive form of OI (MIM #615220) in several consanguineous families [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/26-29\" class=\"abstract_t\">26-29</a>]. WNT1 plays a role in osteoblast function, bone development, and fetal brain development. This form of OI is characterized by moderate to severe disease, with early-onset fractures, decreased bone density, long bone deformities, and short stature. Some patients have brain abnormalities, learning <span class=\"nowrap\">and/or</span> developmental delay, and blue sclera. Tooth development and hearing are normal. Single heterozygous mutations in <em>WNT1</em> cause early-onset osteoporosis. (See <a href=\"topic.htm?path=normal-skeletal-development-and-regulation-of-bone-formation-and-resorption#H593753\" class=\"medical medical_review\">&quot;Normal skeletal development and regulation of bone formation and resorption&quot;, section on 'Wnt signaling pathway'</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">DISEASE CLASSIFICATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>OI is classified into nine major subtypes based on genetic, radiographic, and clinical characteristics (<a href=\"image.htm?imageKey=PEDS%2F78737\" class=\"graphic graphic_table graphicRef78737 \">table 1</a> and <a href=\"image.htm?imageKey=PEDS%2F73256\" class=\"graphic graphic_table graphicRef73256 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/3,14,30,31\" class=\"abstract_t\">3,14,30,31</a>]. A more useful clinical classification, based upon the typical problems that manifest in infants, children, and adults with mild, moderate to severe, and lethal disease [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/32\" class=\"abstract_t\">32</a>], is presented below.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span></p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Overview</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical manifestations vary substantially within families [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/33\" class=\"abstract_t\">33</a>]. One member may be significantly affected clinically, whereas another member with the same mutation may have normal function. This emphasizes that identifying a mutation in a particular gene does not necessarily result in a clear clinical diagnosis and suggests that it may take defects in other connective tissue components to fully express the genetic syndrome of clinically observable OI. (See <a href=\"#H12\" class=\"local\">'Diagnosis'</a> below.)</p><p>Clinical manifestations of OI include (<a href=\"image.htm?imageKey=PEDS%2F78737\" class=\"graphic graphic_table graphicRef78737 \">table 1</a> and <a href=\"image.htm?imageKey=PEDS%2F73256\" class=\"graphic graphic_table graphicRef73256 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/33-36\" class=\"abstract_t\">33-36</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Excess or atypical fractures (brittle bones) [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/37\" class=\"abstract_t\">37</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Short stature</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Scoliosis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basilar skull deformities, which may cause nerve compression or other neurologic symptoms</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Blue sclerae (<a href=\"image.htm?imageKey=ALLRG%2F51775\" class=\"graphic graphic_picture graphicRef51775 \">picture 1</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hearing loss (usually detected in later childhood to early adulthood)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Opalescent teeth that wear quickly (dentinogenesis imperfecta) (<a href=\"image.htm?imageKey=PEDS%2F68896\" class=\"graphic graphic_picture graphicRef68896 \">picture 2</a>) (see <a href=\"topic.htm?path=developmental-defects-of-the-teeth#H22\" class=\"medical medical_review\">&quot;Developmental defects of the teeth&quot;, section on 'Dentinogenesis imperfecta'</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased laxity of the ligaments and skin</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Wormian bones (small, irregular bones along the cranial sutures) [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/38\" class=\"abstract_t\">38</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Easy bruisability</p><p/><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Mild (type I)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bone fragility is the least severe in type I OI [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/34\" class=\"abstract_t\">34</a>]. The fracture rate is variable. Individuals with type I OI may have few or no fractures before puberty or numerous fractures throughout their lives [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/33,39\" class=\"abstract_t\">33,39</a>]. Deformity is minimal, and stature is usually normal [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/40\" class=\"abstract_t\">40</a>]. Individuals with type I OI occasionally present in the perinatal period with intrauterine femoral bowing or fractures [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/33,41\" class=\"abstract_t\">33,41</a>], but they usually do not begin to have fractures until they begin toddling or walking [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/42\" class=\"abstract_t\">42</a>]. The most frequently involved bones are the long bones of the arms and legs, ribs, and the small bones of the hands and feet. The frequency of fractures declines after puberty [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/33\" class=\"abstract_t\">33</a>].</p><p>Adults with OI type I may present with premature or accelerated osteoporosis following menopause. In addition, adults may present with premature hearing loss. In one study of 133 adults with type I OI, 58 percent had hearing loss confirmed by audiometric evaluation, predominantly mixed conductive and sensorineural that began in the second to fourth decade of life and was generally progressive, and 17 percent had subjective hearing impairment with normal audiometry [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/43\" class=\"abstract_t\">43</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Moderate to severe (types III to IX)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bone fragility is moderate to severe in patients with OI types III, IV, V, VI, VII VIII, and IX [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/34\" class=\"abstract_t\">34</a>]. Those with OI type III are most severely affected. However, children with OI type VII and VIII may also develop a severe, lethal type of OI resembling OI type II as described below.</p><p>Children with OI of these types have an increased number and frequency of fractures, mild to moderate bone deformities, kyphoscoliosis, and variable short stature [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/17,34\" class=\"abstract_t\">17,34</a>]. Some children are immobile and require motorized wheelchairs. In addition, children may develop ossicular dislocation, stapes fixation, or fracture of the ossicles, resulting in conductive hearing loss. (See <a href=\"topic.htm?path=hearing-impairment-in-children-evaluation\" class=\"medical medical_review\">&quot;Hearing impairment in children: Evaluation&quot;</a> and <a href=\"topic.htm?path=hearing-loss-in-children-treatment\" class=\"medical medical_review\">&quot;Hearing loss in children: Treatment&quot;</a>.)</p><p>Adults with moderate OI develop hearing loss and osteoporosis, similar to adults with mild OI. However, the onset may be earlier and the expression more intense. Mothers are prone to accelerated bone loss following pregnancy and breastfeeding. Aging and physical inactivity also accelerate OI-related osteoporosis. Hypermobility of the joints of the hands, wrists, and feet can cause pain and decreased function requiring orthopedic intervention. Cardiovascular abnormalities are more common in patients with OI, particularly type III, compared with the general population [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/44\" class=\"abstract_t\">44</a>].</p><p>The practical aspect of identifying moderate to severe OI is that bisphosphonate therapy is helpful in these patients. (See <a href=\"topic.htm?path=osteogenesis-imperfecta-management-and-prognosis#H13635515\" class=\"medical medical_review\">&quot;Osteogenesis imperfecta: Management and prognosis&quot;, section on 'Bisphosphonate therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Lethal perinatal form (type II)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with lethal perinatal OI (type II) usually die in utero or in early infancy. Severe fractures and pulmonary failure are typical problems that accelerate death in this group. Genetic counseling is indicated for affected families. Treatment of OI type II is supportive.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">LABORATORY FINDINGS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although biochemical parameters of bone and mineral metabolism are usually normal in OI, some abnormalities may be noted, including:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Elevated levels of serum alkaline phosphatase have been reported in type VI OI, reflecting impaired bone mineralization [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/30\" class=\"abstract_t\">30</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypercalciuria is common in OI children, and its magnitude appears to reflect the severity of the skeletal disease. One study found increased urinary excretion of calcium in 36 percent of children with OI [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/45\" class=\"abstract_t\">45</a>]. The children with hypercalciuria were of shorter stature and had a greater lifelong fracture rate compared with OI children with normal urinary calcium excretion. However, their renal function was not compromised [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/46\" class=\"abstract_t\">46</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Markers of bone formation (C-terminal propeptide of type I procollagen) may be lower, and markers of bone resorption (C-telopeptide of type I collagen) can be higher in OI, particularly in severely affected subjects [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/47\" class=\"abstract_t\">47</a>].</p><p/><p class=\"headingAnchor\" id=\"H5114631\"><span class=\"h1\">PATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bone histology may show disorganized (woven) bone, especially in more severely affected children. A bone biopsy study in 70 children with types I, III, and IV OI demonstrated normal mineralization with significant reductions in cortical width, cancellous bone volume, trabecular number, and trabecular width [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/48\" class=\"abstract_t\">48</a>]. This study also found significantly increased bone remodeling (turnover) in all types of OI studied (ie, approximately a 70 percent increase compared with age-matched controls). The latter observation provides a rationale for the use of bisphosphonates in children with OI. Bone remodeling, however, is normal in type VI OI, which is characterized by defective mineralization [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/30\" class=\"abstract_t\">30</a>], and, thus, bisphosphonates should not be prescribed to these children. (See <a href=\"topic.htm?path=osteogenesis-imperfecta-management-and-prognosis\" class=\"medical medical_review\">&quot;Osteogenesis imperfecta: Management and prognosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical diagnosis of OI is based on the signs and symptoms described above. The diagnosis is usually straightforward in individuals with bone fragility and a positive family history or several extraskeletal manifestations [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/34\" class=\"abstract_t\">34</a>]. However, in the absence of these features, diagnosis may be difficult. Extraskeletal manifestations can be subclinical (eg, hearing loss [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/43,49-51\" class=\"abstract_t\">43,49-51</a>]), nonspecific (eg, dark or bluish sclerae are commonly present in infants, limiting the usefulness of this sign in this age group), or more obvious at certain ages (eg, dentinogenesis imperfecta may be more noticeable in the primary than the permanent dentition [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/52\" class=\"abstract_t\">52</a>]). (See <a href=\"#H6\" class=\"local\">'Clinical manifestations'</a> above.)</p><p>There is no definitive, readily available lab test for OI. However, research labs have made advances in molecular genetic testing that will eventually be more accessible. The types of tests available for the various genetic defects and laboratories that perform them can be found on the <a href=\"http://www.ncbi.nlm.nih.gov/gtr/&amp;token=ODIqmPyH03K5IrNHL4oottyJV+tPhS7Gs3UPQx+He7Xh4E9j4nqEtGCcPjsW+wBz&amp;TOPIC_ID=2943\" target=\"_blank\" class=\"external\">Genetic Testing Registry (GTR) website</a>. The structure and quantity of type I collagen can be determined in vitro from fibroblast culture using a small skin biopsy. Abnormalities either in quantity or quality of type I collagen are present in approximately 90 percent of OI cases. Sequence analysis of cDNA (which requires skin biopsy for fibroblast culture) or genomic DNA testing of white blood cells for mutations in <em>COL1A1</em> and <em>COL1A2</em> can detect 90 percent or more of all collagen type I mutations [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/34,53,54\" class=\"abstract_t\">34,53,54</a>]. Negative studies do not exclude the diagnosis, because of the OI types that are not associated with type I collagen mutations (types II B and types V through IX) and the false negative rate of approximately 10 percent.</p><p>Prenatal diagnosis of OI is discussed in detail separately. (See <a href=\"topic.htm?path=approach-to-prenatal-diagnosis-of-the-lethal-skeletal-dysplasias\" class=\"medical medical_review\">&quot;Approach to prenatal diagnosis of the lethal skeletal dysplasias&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of OI includes inflicted injury (child abuse) and a variety of skeletal conditions associated with bone fragility, including rickets and osteomalacia.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Child abuse</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children with inflicted trauma have multiple fractures in various stages of healing, similar to children with moderate to severe types of OI. They also may have metaphyseal, rib, and skull fractures. OI is a well-recognized cause of fractures that occur with minimal or no witnessed trauma, but it is a rare disorder and consequently is seldom the cause of such fractures. The differentiation between OI and child abuse is discussed in detail elsewhere. (See <a href=\"topic.htm?path=differential-diagnosis-of-the-orthopedic-manifestations-of-child-abuse#H13\" class=\"medical medical_review\">&quot;Differential diagnosis of the orthopedic manifestations of child abuse&quot;, section on 'Osteogenesis imperfecta'</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Rickets</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rickets can cause slow growth, bone deformities, elevation of alkaline phosphatase, defective bone mineralization, and in some forms, abnormal tooth formation. However, scleral abnormalities and hearing loss typically do not occur. Radiographic findings in rickets are characteristic and include an increased width of the epiphyseal plate, irregular hazy margins of the distal metaphysis, and marginal metaphyseal overgrowth that results in a ball-in-cup-like appearance. (See <a href=\"topic.htm?path=overview-of-rickets-in-children\" class=\"medical medical_review\">&quot;Overview of rickets in children&quot;</a>.)</p><p>Vitamin D-resistant rickets in children, or osteomalacia in adults, may be associated with hypophosphatemia. (See <a href=\"topic.htm?path=causes-of-hypophosphatemia\" class=\"medical medical_review\">&quot;Causes of hypophosphatemia&quot;</a> and <a href=\"topic.htm?path=hereditary-hypophosphatemic-rickets-and-tumor-induced-osteomalacia\" class=\"medical medical_review\">&quot;Hereditary hypophosphatemic rickets and tumor-induced osteomalacia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Osteomalacia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Osteomalacia in adults can cause bone pain, insufficiency fractures, and alkaline phosphatase elevation, but neither hearing loss nor blue sclerae. The most common radiologic finding in osteomalacia is reduced bone density; other abnormalities include Looser's zones or pseudofractures (<a href=\"image.htm?imageKey=ENDO%2F52768\" class=\"graphic graphic_diagnosticimage graphicRef52768 \">image 1</a>), narrow lines of radiolucency at the cortical margins of bones, and the loss of distinctiveness of trabeculae in vertebral bodies. (See <a href=\"topic.htm?path=epidemiology-and-etiology-of-osteomalacia\" class=\"medical medical_review\">&quot;Epidemiology and etiology of osteomalacia&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-osteomalacia\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and treatment of osteomalacia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Other skeletal syndromes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other skeletal syndromes with moderate to severe bone fragility <span class=\"nowrap\">and/or</span> deformity include [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/34\" class=\"abstract_t\">34</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bruck syndrome &ndash; Bruck syndrome (MIM #312750 and %259450), previously called OI with congenital joint contractures, is an autosomal recessive disorder [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/34\" class=\"abstract_t\">34</a>]. Clinical features that distinguish it from OI include congenital contractures of the knees, ankles, and feet; webbing (pterygia) of the elbow and knee; and clubfoot (talipes equinovarus) [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/55\" class=\"abstract_t\">55</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Osteoporosis-pseudoglioma syndrome &ndash; Osteoporosis-pseudoglioma syndrome (MIM #259770) is an autosomal recessive disorder that was previously called the ocular form of OI [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/34,56-58\" class=\"abstract_t\">34,56-58</a>]. It is caused by deletion of the gene for low-density-lipoprotein (LDL) receptor-related protein 5 (LRP-5). Other characteristic findings include microcephaly; pseudoglioma (inflammatory changes of the vitreous body, secondary to iridochoroiditis, that mimic retinal glioma); blindness (with onset in infancy); vitreoretinal abnormalities; cataract; absent anterior chamber; iris atrophy; intraocular calcification; and hypotonia [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/59,60\" class=\"abstract_t\">59,60</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Panostotic fibrous dysplasia &ndash; Panostotic fibrous dysplasia, the extreme form of polyostotic fibrous dysplasia (McCune-Albright syndrome, MIM #174800), is caused by a somatic mutation in the guanine nucleotide stimulatory protein (<em>GNAS1</em>) gene [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/34,61\" class=\"abstract_t\">34,61</a>]. It is characterized by cystic or ground glass lesions in <strong>all</strong> bones. (See <a href=\"topic.htm?path=benign-bone-tumors-in-children-and-adolescents#H22\" class=\"medical medical_review\">&quot;Benign bone tumors in children and adolescents&quot;, section on 'Fibrous dysplasia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Juvenile Paget disease &ndash; Juvenile Paget disease (MIM #239000), also known as idiopathic hyperphosphatasia, is an autosomal recessive disorder [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/34,62\" class=\"abstract_t\">34,62</a>]. Patients with idiopathic hyperphosphatasia have increased serum alkaline phosphatase, which distinguishes it from OI, in which alkaline phosphatase is usually normal. However, elevated levels of serum alkaline phosphatase have been reported in some patients with type VI OI [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/30\" class=\"abstract_t\">30</a>]. (See <a href=\"topic.htm?path=transient-hyperphosphatasemia-of-infancy-and-early-childhood\" class=\"medical medical_review\">&quot;Transient hyperphosphatasemia of infancy and early childhood&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-paget-disease-of-bone\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of Paget disease of bone&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypophosphatasia &ndash; Hypophosphatasia (MIM #241500) is a rare, autosomal disease caused by a deficiency of tissue nonspecific alkaline phosphatase and characterized by abnormal mineralization of bone and dental tissues [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/34,63\" class=\"abstract_t\">34,63</a>]. Patients with hypophosphatasia have decreased serum concentrations of alkaline phosphatase, which distinguishes it from OI. (See <a href=\"topic.htm?path=periodontal-disease-in-children-associated-systemic-conditions#H11\" class=\"medical medical_review\">&quot;Periodontal disease in children: Associated systemic conditions&quot;, section on 'Hypophosphatasia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cole-Carpenter syndrome &ndash; The inheritance pattern of Cole-Carpenter syndrome (MIM 112240) is unknown. It is characterized by osteoporosis, short stature, craniosynostosis, hydrocephalus, and proptosis [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/64\" class=\"abstract_t\">64</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Idiopathic juvenile osteoporosis &ndash; Idiopathic juvenile osteoporosis is a nonhereditary form of transient, isolated childhood osteoporosis that occurs in prepubertal, previously healthy children [<a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/65\" class=\"abstract_t\">65</a>].</p><p/><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Osteogenesis imperfecta (OI) is a rare inherited connective tissue disorder with many phenotypic presentations. Severely affected patients suffer multiple fractures with minimal or no trauma, and infants with the worst form of OI die in the perinatal period. Mild forms of OI may be manifested by only premature osteoporosis or severe postmenopausal bone mineral loss. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H6\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>OI is most commonly caused by autosomal dominant mutations in genes encoding the alpha-1 and alpha-2 chains of type I collagen (<em>COL1A1</em> and <em>COL1A2</em>). The autosomal recessive forms are caused by mutations in genes encoding proteins involved in posttranslational modification of type I collagen (FK506-binding protein 10 [<em>FKBP10</em>], cartilage-associated protein [<em>CRTAP</em>], leprecan-like 1 [<em>LEPRE1</em>], peptidyl-prolyl isomerase B [<em>PPIB</em>]) or other mechanisms of bone formation and homeostasis (serpin peptidase inhibitor, clade, H, member 1 [<em>SERPINH1</em>]; serpin peptidase inhibitor, clade F, member 1 [<em>SERPINF1</em>]; specificity protein 7 [<em>SP7</em>]<em><span class=\"nowrap\">/</em>osterix</span> [<em>OSX</em>]; interferon-induced transmembrane protein 5 [<em>IFITM5</em>]) (<a href=\"image.htm?imageKey=PEDS%2F78737\" class=\"graphic graphic_table graphicRef78737 \">table 1</a>). (See <a href=\"#H3\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>OI is classified into nine major subtypes based on genetic, radiographic, and clinical characteristics. It can also be classified by clinical severity. (See <a href=\"#H5\" class=\"local\">'Disease classification'</a> above and <a href=\"#H6\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis should be considered in patients who have bone fragility and any of the following clinical manifestations (<a href=\"image.htm?imageKey=PEDS%2F78737\" class=\"graphic graphic_table graphicRef78737 \">table 1</a> and <a href=\"image.htm?imageKey=PEDS%2F73256\" class=\"graphic graphic_table graphicRef73256 \">table 2</a>) (see <a href=\"#H6\" class=\"local\">'Clinical manifestations'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Short stature</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Scoliosis</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Basilar skull deformities</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Blue sclerae (<a href=\"image.htm?imageKey=ALLRG%2F51775\" class=\"graphic graphic_picture graphicRef51775 \">picture 1</a>)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Hearing loss</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Opalescent teeth that wear quickly (dentinogenesis imperfecta) (<a href=\"image.htm?imageKey=PEDS%2F68896\" class=\"graphic graphic_picture graphicRef68896 \">picture 2</a>)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Increased laxity of the ligaments and skin</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Wormian bones (small, irregular bones along the cranial sutures)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Easy bruisability</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The differential diagnosis includes child abuse, rickets, osteomalacia, and other rare skeletal syndromes. The diagnosis usually can be made clinically in patients with a positive history <span class=\"nowrap\">and/or</span> several extraskeletal manifestations. However, the diagnosis can be difficult in the absence of these features. Skin biopsy for analysis of type I collagen genes <span class=\"nowrap\">and/or</span> testing of genomic DNA for mutations in <em>COL1A1</em> and <em>COL1A2</em> may be helpful. However, normal results of these tests do not exclude the diagnosis. (See <a href=\"#H12\" class=\"local\">'Diagnosis'</a> above and <a href=\"#H13\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/1\" class=\"nounderline abstract_t\">Marini JC. Osteogenesis imperfecta: comprehensive management. Adv Pediatr 1988; 35:391.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/2\" class=\"nounderline abstract_t\">Prockop DJ, Kivirikko KI. Heritable diseases of collagen. N Engl J Med 1984; 311:376.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/3\" class=\"nounderline abstract_t\">Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979; 16:101.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/4\" class=\"nounderline abstract_t\">Cohn DH, Byers PH, Steinmann B, Gelinas RE. Lethal osteogenesis imperfecta resulting from a single nucleotide change in one human pro alpha 1(I) collagen allele. Proc Natl Acad Sci U S A 1986; 83:6045.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/5\" class=\"nounderline abstract_t\">Byers PH, Starman BJ, Cohn DH, Horwitz AL. A novel mutation causes a perinatal lethal form of osteogenesis imperfecta. An insertion in one alpha 1(I) collagen allele (COL1A1). J Biol Chem 1988; 263:7855.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/6\" class=\"nounderline abstract_t\">Cohn DH, Apone S, Eyre DR, et al. Substitution of cysteine for glycine within the carboxyl-terminal telopeptide of the alpha 1 chain of type I collagen produces mild osteogenesis imperfecta. J Biol Chem 1988; 263:14605.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/7\" class=\"nounderline abstract_t\">Gajko-Galicka A. Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans. Acta Biochim Pol 2002; 49:433.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/8\" class=\"nounderline abstract_t\">Cho TJ, Lee KE, Lee SK, et al. A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet 2012; 91:343.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/9\" class=\"nounderline abstract_t\">Semler O, Garbes L, Keupp K, et al. A mutation in the 5'-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. Am J Hum Genet 2012; 91:349.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/10\" class=\"nounderline abstract_t\">Alanay Y, Avaygan H, Camacho N, et al. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 2010; 86:551.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/11\" class=\"nounderline abstract_t\">Tonachini L, Morello R, Monticone M, et al. cDNA cloning, characterization and chromosome mapping of the gene encoding human cartilage associated protein (CRTAP). Cytogenet Cell Genet 1999; 87:191.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/12\" class=\"nounderline abstract_t\">Baldridge D, Schwarze U, Morello R, et al. CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta. Hum Mutat 2008; 29:1435.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/13\" class=\"nounderline abstract_t\">Barnes AM, Chang W, Morello R, et al. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N Engl J Med 2006; 355:2757.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/14\" class=\"nounderline abstract_t\">Ward LM, Rauch F, Travers R, et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 2002; 31:12.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/15\" class=\"nounderline abstract_t\">Labuda M, Morissette J, Ward LM, et al. Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone 2002; 31:19.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/16\" class=\"nounderline abstract_t\">Vranka JA, Sakai LY, B&auml;chinger HP. Prolyl 3-hydroxylase 1, enzyme characterization and identification of a novel family of enzymes. J Biol Chem 2004; 279:23615.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/17\" class=\"nounderline abstract_t\">Cabral WA, Chang W, Barnes AM, et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet 2007; 39:359.</a></li><li class=\"breakAll\">Osteogenesis imperfecta, type VIII. In: Online Mendelian Inheritance in Man. Johns Hopkins University Press, Baltimore. www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=610915 (Accessed on April 10, 2007).</li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/19\" class=\"nounderline abstract_t\">van Dijk FS, Nikkels PG, den Hollander NS, et al. Lethal/severe osteogenesis imperfecta in a large family: a novel homozygous LEPRE1 mutation and bone histological findings. Pediatr Dev Pathol 2011; 14:228.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/20\" class=\"nounderline abstract_t\">van Dijk FS, Nesbitt IM, Zwikstra EH, et al. PPIB mutations cause severe osteogenesis imperfecta. Am J Hum Genet 2009; 85:521.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/21\" class=\"nounderline abstract_t\">Barnes AM, Carter EM, Cabral WA, et al. Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. N Engl J Med 2010; 362:521.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/22\" class=\"nounderline abstract_t\">Pyott SM, Schwarze U, Christiansen HE, et al. Mutations in PPIB (cyclophilin B) delay type I procollagen chain association and result in perinatal lethal to moderate osteogenesis imperfecta phenotypes. Hum Mol Genet 2011; 20:1595.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/23\" class=\"nounderline abstract_t\">Christiansen HE, Schwarze U, Pyott SM, et al. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet 2010; 86:389.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/24\" class=\"nounderline abstract_t\">Becker J, Semler O, Gilissen C, et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 2011; 88:362.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/25\" class=\"nounderline abstract_t\">Lapunzina P, Aglan M, Temtamy S, et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am J Hum Genet 2010; 87:110.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/26\" class=\"nounderline abstract_t\">Laine CM, Joeng KS, Campeau PM, et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N Engl J Med 2013; 368:1809.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/27\" class=\"nounderline abstract_t\">Keupp K, Beleggia F, Kayserili H, et al. Mutations in WNT1 cause different forms of bone fragility. Am J Hum Genet 2013; 92:565.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/28\" class=\"nounderline abstract_t\">Fahiminiya S, Majewski J, Mort J, et al. Mutations in WNT1 are a cause of osteogenesis imperfecta. J Med Genet 2013; 50:345.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/29\" class=\"nounderline abstract_t\">Pyott SM, Tran TT, Leistritz DF, et al. WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am J Hum Genet 2013; 92:590.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/30\" class=\"nounderline abstract_t\">Glorieux FH, Ward LM, Rauch F, et al. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 2002; 17:30.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/31\" class=\"nounderline abstract_t\">Glorieux FH, Rauch F, Plotkin H, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 2000; 15:1650.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/32\" class=\"nounderline abstract_t\">Antoniazzi F, Mottes M, Fraschini P, et al. Osteogenesis imperfecta: practical treatment guidelines. Paediatr Drugs 2000; 2:465.</a></li><li class=\"breakAll\">Byers PH. Disorders of collagen biosynthesis and structure. In: The metabolic and molecular bases of inherited disease, 8th ed, Scriver C, Beaudet AL, Valle D, Sly W (Eds), McGraw-Hill, New York 2001. p.5241.</li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/34\" class=\"nounderline abstract_t\">Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004; 363:1377.</a></li><li class=\"breakAll\">Osteogenesis imperfecta. In: Preventive management of children with congenital anomalies and syndromes, Wilson GN, Cooley WC (Eds), Cambridge University Press, Cambridge, UK 2000. p.256.</li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/36\" class=\"nounderline abstract_t\">Cremin B, Goodman H, Spranger J, Beighton P. Wormian bones in osteogenesis imperfecta and other disorders. Skeletal Radiol 1982; 8:35.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/37\" class=\"nounderline abstract_t\">Greeley CS, Donaruma-Kwoh M, Vettimattam M, et al. Fractures at diagnosis in infants and children with osteogenesis imperfecta. J Pediatr Orthop 2013; 33:32.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/38\" class=\"nounderline abstract_t\">Semler O, Cheung MS, Glorieux FH, Rauch F. Wormian bones in osteogenesis imperfecta: Correlation to clinical findings and genotype. Am J Med Genet A 2010; 152A:1681.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/39\" class=\"nounderline abstract_t\">Plotkin H. Syndromes with congenital brittle bones. BMC Pediatr 2004; 4:16.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/40\" class=\"nounderline abstract_t\">Graff K, Syczewska M. Developmental charts for children with osteogenesis imperfecta, type I (body height, body weight and BMI). Eur J Pediatr 2017; 176:311.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/41\" class=\"nounderline abstract_t\">Smith R. Osteogenesis imperfecta. Clin Rheum Dis 1986; 12:655.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/42\" class=\"nounderline abstract_t\">Carty H. Brittle or battered. Arch Dis Child 1988; 63:350.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/43\" class=\"nounderline abstract_t\">Kuurila K, Kaitila I, Johansson R, Gr&eacute;nman R. Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey. Ann Otol Rhinol Laryngol 2002; 111:939.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/44\" class=\"nounderline abstract_t\">Radunovic Z, Wekre LL, Diep LM, Steine K. Cardiovascular abnormalities in adults with osteogenesis imperfecta. Am Heart J 2011; 161:523.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/45\" class=\"nounderline abstract_t\">Chines A, Petersen DJ, Schranck FW, Whyte MP. Hypercalciuria in children severely affected with osteogenesis imperfecta. J Pediatr 1991; 119:51.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/46\" class=\"nounderline abstract_t\">Chines A, Boniface A, McAlister W, Whyte M. Hypercalciuria in osteogenesis imperfecta: a follow-up study to assess renal effects. Bone 1995; 16:333.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/47\" class=\"nounderline abstract_t\">Lund AM, Hansen M, Kollerup G, et al. Collagen-derived markers of bone metabolism in osteogenesis imperfecta. Acta Paediatr 1998; 87:1131.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/48\" class=\"nounderline abstract_t\">Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 2000; 26:581.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/49\" class=\"nounderline abstract_t\">Pedersen U. Hearing loss in patients with osteogenesis imperfecta. A clinical and audiological study of 201 patients. Scand Audiol 1984; 13:67.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/50\" class=\"nounderline abstract_t\">Kuurila K, Gr&eacute;nman R, Johansson R, Kaitila I. Hearing loss in children with osteogenesis imperfecta. Eur J Pediatr 2000; 159:515.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/51\" class=\"nounderline abstract_t\">Paterson CR, Monk EA, McAllion SJ. How common is hearing impairment in osteogenesis imperfecta? J Laryngol Otol 2001; 115:280.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/52\" class=\"nounderline abstract_t\">Petersen K, Wetzel WE. Recent findings in classification of osteogenesis imperfecta by means of existing dental symptoms. ASDC J Dent Child 1998; 65:305.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/53\" class=\"nounderline abstract_t\">Wenstrup RJ, Willing MC, Starman BJ, Byers PH. Distinct biochemical phenotypes predict clinical severity in nonlethal variants of osteogenesis imperfecta. Am J Hum Genet 1990; 46:975.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/54\" class=\"nounderline abstract_t\">K&ouml;rkk&ouml; J, Ala-Kokko L, De Paepe A, et al. Analysis of the COL1A1 and COL1A2 genes by PCR amplification and scanning by conformation-sensitive gel electrophoresis identifies only COL1A1 mutations in 15 patients with osteogenesis imperfecta type I: identification of common sequences of null-allele mutations. Am J Hum Genet 1998; 62:98.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/55\" class=\"nounderline abstract_t\">McPherson E, Clemens M. Bruck syndrome (osteogenesis imperfecta with congenital joint contractures): review and report on the first North American case. Am J Med Genet 1997; 70:28.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/56\" class=\"nounderline abstract_t\">Beighton P, Winship I, Behari D. The ocular form of osteogenesis imperfecta: a new autosomal recessive syndrome. Clin Genet 1985; 28:69.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/57\" class=\"nounderline abstract_t\">Capoen J, De Paepe A, Lauwers H. The osteoporosis pseudoglioma syndrome. J Belge Radiol 1993; 76:224.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/58\" class=\"nounderline abstract_t\">Beighton P. Osteoporosis-pseudoglioma syndrome. Clin Genet 1986; 29:263.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/59\" class=\"nounderline abstract_t\">Frontali M, Stomeo C, Dallapiccola B. Osteoporosis-pseudoglioma syndrome: report of three affected sibs and an overview. Am J Med Genet 1985; 22:35.</a></li><li class=\"breakAll\">Osteoporosis-pseudoglioma syndrome; OPPG. In: Online Mendelian Inheritance in Man. Johns Hopkins University Press, Baltimore. http://www.ncbi.nlm.nih.gov/omim/259770 (Accessed on April 25, 2005).</li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/61\" class=\"nounderline abstract_t\">Cole DE, Fraser FC, Glorieux FH, et al. Panostotic fibrous dysplasia: a congenital disorder of bone with unusual facial appearance, bone fragility, hyperphosphatasemia, and hypophosphatemia. Am J Med Genet 1983; 14:725.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/62\" class=\"nounderline abstract_t\">Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002; 347:175.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/63\" class=\"nounderline abstract_t\">Whyte MP. Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. Endocr Rev 1994; 15:439.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/64\" class=\"nounderline abstract_t\">Cole DE, Carpenter TO. Bone fragility, craniosynostosis, ocular proptosis, hydrocephalus, and distinctive facial features: a newly recognized type of osteogenesis imperfecta. J Pediatr 1987; 110:76.</a></li><li><a href=\"https://www.uptodate.com/contents/osteogenesis-imperfecta-clinical-features-and-diagnosis/abstract/65\" class=\"nounderline abstract_t\">Smith R. Idiopathic juvenile osteoporosis: experience of twenty-one patients. Br J Rheumatol 1995; 34:68.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2943 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H18\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">PATHOGENESIS</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">DISEASE CLASSIFICATION</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Overview</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Mild (type I)</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Moderate to severe (types III to IX)</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Lethal perinatal form (type II)</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">LABORATORY FINDINGS</a></li><li><a href=\"#H5114631\" id=\"outline-link-H5114631\">PATHOLOGY</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">DIAGNOSIS</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">DIFFERENTIAL DIAGNOSIS</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">Child abuse</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Rickets</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Osteomalacia</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Other skeletal syndromes</a></li></ul></li><li><a href=\"#H18\" id=\"outline-link-H18\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ALLRG/2943|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/52768\" class=\"graphic graphic_diagnosticimage\">- Pseudofractures in osteomalacia</a></li></ul></li><li><div id=\"ALLRG/2943|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/77562\" class=\"graphic graphic_figure\">- Tropocollagen synthesis</a></li></ul></li><li><div id=\"ALLRG/2943|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ALLRG/51775\" class=\"graphic graphic_picture\">- Blue sclerae</a></li><li><a href=\"image.htm?imageKey=PEDS/68896\" class=\"graphic graphic_picture\">- Dentinogenesis imperfecta in patient with osteogenesis imperfect</a></li></ul></li><li><div id=\"ALLRG/2943|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/78737\" class=\"graphic graphic_table\">- OI clinical features</a></li><li><a href=\"image.htm?imageKey=PEDS/73256\" class=\"graphic graphic_table\">- OI radiographic features</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-prenatal-diagnosis-of-the-lethal-skeletal-dysplasias\" class=\"medical medical_review\">Approach to prenatal diagnosis of the lethal skeletal dysplasias</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=benign-bone-tumors-in-children-and-adolescents\" class=\"medical medical_review\">Benign bone tumors in children and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bone-physiology-and-biochemical-markers-of-bone-turnover\" class=\"medical medical_review\">Bone physiology and biochemical markers of bone turnover</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-of-hypophosphatemia\" class=\"medical medical_review\">Causes of hypophosphatemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-paget-disease-of-bone\" class=\"medical medical_review\">Clinical manifestations and diagnosis of Paget disease of bone</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-osteomalacia\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and treatment of osteomalacia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=developmental-defects-of-the-teeth\" class=\"medical medical_review\">Developmental defects of the teeth</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=differential-diagnosis-of-the-orthopedic-manifestations-of-child-abuse\" class=\"medical medical_review\">Differential diagnosis of the orthopedic manifestations of child abuse</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-etiology-of-osteomalacia\" class=\"medical medical_review\">Epidemiology and etiology of osteomalacia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hearing-impairment-in-children-evaluation\" class=\"medical medical_review\">Hearing impairment in children: Evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hearing-loss-in-children-treatment\" class=\"medical medical_review\">Hearing loss in children: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hereditary-hypophosphatemic-rickets-and-tumor-induced-osteomalacia\" class=\"medical medical_review\">Hereditary hypophosphatemic rickets and tumor-induced osteomalacia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=normal-skeletal-development-and-regulation-of-bone-formation-and-resorption\" class=\"medical medical_review\">Normal skeletal development and regulation of bone formation and resorption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=osteogenesis-imperfecta-management-and-prognosis\" class=\"medical medical_review\">Osteogenesis imperfecta: Management and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-rickets-in-children\" class=\"medical medical_review\">Overview of rickets in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=periodontal-disease-in-children-associated-systemic-conditions\" class=\"medical medical_review\">Periodontal disease in children: Associated systemic conditions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=transient-hyperphosphatasemia-of-infancy-and-early-childhood\" class=\"medical medical_review\">Transient hyperphosphatasemia of infancy and early childhood</a></li></ul></div></div>","javascript":null}